Showing results (401-410 of 463) with videos related to

Sort By:
Pageof 47
Clinical Transplantation|July 18, 2024
Cardio-Renal-Metabolic Outcomes Associated With the Use of GLP-1 Receptor Agonists After Heart TransplantationElena M Donald, Elissa Driggin, Jason Choe, et al.
The Review of Scientific Instruments|July 2, 2010
Diagnostics for first plasma and development plan on KSTARJ H Lee, H K Na, S G Lee, et al.
Cancer Cell|November 14, 2018
JARID2 Functions as a Tumor Suppressor in Myeloid Neoplasms by Repressing Self-Renewal in Hematopoietic Progenitor CellsHamza Celik, Won Kyun Koh, Ashley C Kramer, et al.
The Journal of Experimental Medicine|March 23, 2019
PIP4K2A as a negative regulator of PI3K in PTEN-deficient glioblastomaYong Jae Shin, Jason K Sa, Yeri Lee, et al.
Nature Cancer|December 29, 2022
DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progressionTim Kong, Angelo B A Laranjeira, Kangning Yang, et al.
Nature Genetics|January 20, 2009
DNA methylation profiles in monozygotic and dizygotic twinsZachary A Kaminsky, Thomas Tang, Sun-Chong Wang, et al.
Blood Advances|September 11, 2020
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trialStephen T Oh, Moshe Talpaz, Aaron T Gerds, et al.
Cancer Discovery|July 1, 2021
A Humanized Animal Model Predicts Clonal Evolution and Therapeutic Vulnerabilities in Myeloproliferative NeoplasmsHamza Celik, Ethan Krug, Christine R Zhang, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 8, 2024
Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With MomelotinibClaire N Harrison, Ruben Mesa, Moshe Talpaz, et al.
The Journal of Clinical Investigation|December 7, 2023
Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasmsFan He, Angelo Ba Laranjeira, Tim Kong, et al.
Pageof 47